As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among ...
Commentary
Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics
Pharmaceutical research and development is organized around prioritized investments, delivering on assets with the greatest return of investments. Linear sequencing of trials and financial risks are d...
Clinical trials of disease stages in COVID 19: complicated and often misinterpreted
This commentary in Lancet discusses the need to understand the various disease states of COVID-19 when interpreting trial results. The majority of clinical trials involve patients who have been ad...
Perspectives on CPT: A Real‐World Evidence Framework for Optimising Dosing in All Patients with COVID‐19
A COVID-19 call to action in Clinical Pharmacology & Therapeutics from Richard Peck, Daniel Weiner, Jack Cook and Bob Powell. “The Global Heads of Clinical Pharmacology from the pharmaceutic...
Commentary on CTS: Time for the global pharmacology community to step up
In this commentary in Clinical and Translational Science, the authors urge the global translational and quantitative pharmacology community to come together and contribute our tools and know-how to fi...
COVID-19 drug development in the critically ill – a “special population”
Commentary by Carl Kirkpatrick, PhD. Professor at Monash University As the number of patients diagnosed with COVID-19 exceeded the 2.5 million worldwide, the impact on the hospital systems in many cou...
Ivermectin is unlikely to be clinically effective for COVID-19.
Commentary by Dr. Craig Rayner and Dr. Karen Yeo Recently in Antiviral research, Caly et al.(1) reported the in vitro activity of ivermectin against SARS-CoV-2 in SERO cells. The study, described th...
Pregnancy and COVID-19
Commentary by Mark Milad, PharmD Introduction According to the CDC, pregnant women seem to have the same risks from COVID-19 as adults who are not pregnant.1 However, pregnant women and newborns are...
COVID-19 drug development in the elderly – a “special population”
Commentary by Tom Polasek, MD, PhD, Director of Clinical Pharmacology, Certara The high morbidity and mortality rates of COVID-19 infection in the elderly highlight the importance of clinical pharmaco...
Optimizing clinical trial design with in silico simulation
by Dr. Keith Nieforth, Senior Director PMX-SW, Certara With the continued advancement of the COVID-19 pandemic, researchers all over the globe are dedicated to finding safe and effective treatments. W...